Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy

RegulatoryapprovedRAG-1CPositive

AI Analysis

Summary

Ractigen Therapeutics announced U.S. FDA IND clearance for RAG-1C, a first-in-class saRNA candidate for proliferative vitreoretinopathy, alongside China CDE clearance, enabling global clinical development using the company's LiCO platform.

Outcome Details

U.S. FDA IND clearance granted; dual IND clearances from both U.S. FDA and China CDE

Importance:7/10

Sentiment:

0.85

IND clearancesaRNA therapyocular diseasefirst-in-classLiCO platformglobal developmentChina CDE

Related Companies

$CBDY $GBCYD $CHHE $TRAX $WHEN

Read the original article

Published by PR Newswire Biotech on July 31, 2026 11:00 AM

Read Original